<DOC>
	<DOCNO>NCT00409253</DOCNO>
	<brief_summary>The aim study confirm URAPIDIL efficient safe NICARDIPINE correct severe hypertension pre-eclamptic patient . - efficacy endpoint : mean arterial blood pressure correct 105-125 mmHg 120 min study drug administration . - safety endpoint : clinical , biological ultrasound observation side effect.All infant observe neonatology unit ( 48h ) .</brief_summary>
	<brief_title>Treatment Severe Hypertension During Pre-Eclampsia : A Preliminary Equivalence Study Between Urapidil Nicardipine</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Pre-Eclampsia</mesh_term>
	<mesh_term>Eclampsia</mesh_term>
	<mesh_term>Urapidil</mesh_term>
	<mesh_term>Nicardipine</mesh_term>
	<criteria>Inclusion criterion : patient 'written informed consent date signed investigator patient affiliation social security system single pregnancy arterial hypertension ( PAS ≥140 and/or PAD≥90 ) context severe preeclampsia Exclusion criterion : patient 18 year old unable give inform consent protocol reject patientimpossibility use non invasive blood pressure monitor antihypertensive treatment within 24h inclusion allergy contraindication one study drugspre eclampsia require antihypertensive treatment acute eclampsiarequirement drug potential dangerous interaction study drug participation therapeutic protocol within 6 month prior start study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>51 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>PRE-ECLAMPSIA-URAPIDIL-NICARDIPINE</keyword>
</DOC>